MA30224B1 - Modulateurs de la kinase de l'aurore et procede d'utilisation - Google Patents
Modulateurs de la kinase de l'aurore et procede d'utilisationInfo
- Publication number
- MA30224B1 MA30224B1 MA31184A MA31184A MA30224B1 MA 30224 B1 MA30224 B1 MA 30224B1 MA 31184 A MA31184 A MA 31184A MA 31184 A MA31184 A MA 31184A MA 30224 B1 MA30224 B1 MA 30224B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- influencing
- relates
- kinase
- aurora kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003989 Aurora kinases Human genes 0.000 abstract 2
- 108090000433 Aurora kinases Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000033366 cell cycle process Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
MODULATEURS DE LA KINASE DE L'AURORE ET PROCÉDÉ D'UTILISATION La présente invention concerne des composés chimiques répondant à la formule générale I dans laquelle A1, A2, C1, C2, D, L1, L2, Z et R1-8 sont définis dans le présent document, et des intermédiaires synthétiques en mesure de moduler diverses enzymes du récepteur de la protéine kinase, influençant ainsi divers états pathologiques liés aux activités de telles kinases. Par exemple, les composés sont en mesure de moduler la kinase de l'aurore, influençant ainsi le processus du cycle cellulaire et la prolifération cellulaire en vue de traiter un cancer et des pathologies liées au cancer. L'invention concerne également des compositions pharmaceutiques comprenant les composés et des procédés visant à traiter des états pathologiques liés à l'activité de la kinase de l'aurore.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76167506P | 2006-01-23 | 2006-01-23 | |
| US11/655,642 US7560551B2 (en) | 2006-01-23 | 2007-01-18 | Aurora kinase modulators and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30224B1 true MA30224B1 (fr) | 2009-02-02 |
Family
ID=40849087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31184A MA30224B1 (fr) | 2006-01-23 | 2008-08-19 | Modulateurs de la kinase de l'aurore et procede d'utilisation |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1984353B1 (fr) |
| JP (2) | JP5280862B2 (fr) |
| KR (2) | KR101332975B1 (fr) |
| AU (2) | AU2007208351C1 (fr) |
| BR (1) | BRPI0706684A2 (fr) |
| CA (1) | CA2637658C (fr) |
| CR (1) | CR10213A (fr) |
| DK (1) | DK1984353T3 (fr) |
| EA (1) | EA018128B1 (fr) |
| ES (1) | ES2502790T3 (fr) |
| GE (1) | GEP20125643B (fr) |
| HR (1) | HRP20160039T1 (fr) |
| HU (1) | HUE028504T2 (fr) |
| IL (1) | IL192812A (fr) |
| MA (1) | MA30224B1 (fr) |
| MY (1) | MY161884A (fr) |
| NO (1) | NO20083639L (fr) |
| NZ (1) | NZ569815A (fr) |
| TN (1) | TNSN08310A1 (fr) |
| WO (1) | WO2007087276A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ569815A (en) * | 2006-01-23 | 2011-11-25 | Amgen Inc | Aurora kinase modulators and method of use |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| MX2010010151A (es) * | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2321298B1 (fr) * | 2008-08-04 | 2013-10-02 | Amgen Inc. | Modulateurs de kinase aurora et procédés d utilisation |
| WO2010019473A1 (fr) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Modulateurs d’aurora kinase et procédés d'utilisation |
| CA2746307C (fr) | 2008-12-17 | 2013-11-19 | Amgen Inc. | Composes aminopyridines et carboxypyridines en tant que inhibiteurs de phosphodiesterase 10 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| ES2444777T3 (es) | 2009-06-12 | 2014-02-26 | Bristol-Myers Squibb Company | Compuestos de nicotinamida útiles como moduladores de quinasas |
| EA020526B1 (ru) | 2009-09-11 | 2014-11-28 | Амген Инк. | Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака |
| EP2688887B1 (fr) | 2011-03-23 | 2015-05-13 | Amgen Inc. | Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3 |
| MX369738B (es) * | 2013-12-03 | 2019-11-20 | Amgen Inc | Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas. |
| JP6483288B2 (ja) | 2015-06-03 | 2019-03-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 心臓血管障害の治療にて用いるための４−ヒドロキシ−３−（ヘテロアリール）ピリジン−２−オン ａｐｊアゴニスト |
| KR20180052635A (ko) | 2015-09-18 | 2018-05-18 | 가켄 세이야쿠 가부시키가이샤 | 바이아릴 유도체 및 이를 포함하는 약제 |
| JP7032903B2 (ja) * | 2016-10-12 | 2022-03-09 | 田辺三菱製薬株式会社 | スルホンアミド化合物の製造方法 |
| CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2020049208A1 (fr) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa comme cible pour traiter, prévenir ou soigner une infection par vih ou le sida |
| CA3155864A1 (fr) | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonistes du recepteur m4 d'acetylcholine muscarinique |
| CN112898292A (zh) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN111302948A (zh) * | 2020-04-13 | 2020-06-19 | 长兴进源新材料科技有限公司 | 一种2,2-双(4-氨基苯基)六氟丙烷合成方法 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121568926A (zh) * | 2023-02-06 | 2026-02-24 | 泰普6治疗公司 | 化合物、组合物及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU770600B2 (en) * | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| PL360439A1 (en) | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| JP4498741B2 (ja) | 2001-12-24 | 2010-07-07 | アストラゼネカ アクチボラグ | オーロラキナーゼ阻害剤としての置換キナゾリン誘導体 |
| CA2473510A1 (fr) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Derives pyrimidine en tant qu'inhibiteurs de kinase rho |
| AU2003299517A1 (en) | 2002-05-23 | 2004-05-25 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0219054D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| WO2004037814A1 (fr) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Compositions indazolinones utiles en tant qu'inhibiteurs des kinases |
| FR2853378B1 (fr) | 2003-04-02 | 2006-03-10 | Carbone Lorraine Composants | Plaquettes de frein a disque ventilees |
| NZ548128A (en) * | 2003-12-29 | 2010-05-28 | Banyu Pharma Co Ltd | Novel 2-heteroaryl-substituted benzimidazole derivative |
| EP1751136B1 (fr) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Derives heterocycliques nitrogenes comme modulateurs de proteines kinases et leurs utilisations pour le traitement de l' angiogenese et le cancer |
| NZ569815A (en) * | 2006-01-23 | 2011-11-25 | Amgen Inc | Aurora kinase modulators and method of use |
-
2007
- 2007-01-22 NZ NZ569815A patent/NZ569815A/en unknown
- 2007-01-22 HR HRP20160039TT patent/HRP20160039T1/hr unknown
- 2007-01-22 DK DK07716912.6T patent/DK1984353T3/en active
- 2007-01-22 CA CA2637658A patent/CA2637658C/fr active Active
- 2007-01-22 EP EP07716912.6A patent/EP1984353B1/fr active Active
- 2007-01-22 KR KR1020117025676A patent/KR101332975B1/ko active Active
- 2007-01-22 EA EA200801732A patent/EA018128B1/ru not_active IP Right Cessation
- 2007-01-22 ES ES11008953.9T patent/ES2502790T3/es active Active
- 2007-01-22 JP JP2008551471A patent/JP5280862B2/ja active Active
- 2007-01-22 MY MYPI20082661A patent/MY161884A/en unknown
- 2007-01-22 AU AU2007208351A patent/AU2007208351C1/en active Active
- 2007-01-22 KR KR1020087020677A patent/KR101300424B1/ko active Active
- 2007-01-22 BR BRPI0706684-8A patent/BRPI0706684A2/pt not_active IP Right Cessation
- 2007-01-22 GE GEAP200710871A patent/GEP20125643B/en unknown
- 2007-01-22 WO PCT/US2007/001714 patent/WO2007087276A1/fr not_active Ceased
- 2007-01-22 HU HUE07716912A patent/HUE028504T2/en unknown
-
2008
- 2008-07-14 IL IL192812A patent/IL192812A/en active IP Right Grant
- 2008-07-21 TN TNP2008000310A patent/TNSN08310A1/en unknown
- 2008-08-18 CR CR10213A patent/CR10213A/es unknown
- 2008-08-19 MA MA31184A patent/MA30224B1/fr unknown
- 2008-08-22 NO NO20083639A patent/NO20083639L/no not_active Application Discontinuation
-
2010
- 2010-11-05 AU AU2010241280A patent/AU2010241280B2/en active Active
-
2013
- 2013-01-23 JP JP2013010303A patent/JP5753546B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30224B1 (fr) | Modulateurs de la kinase de l'aurore et procede d'utilisation | |
| MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
| MX2009010517A (es) | Moduladores de cinasa aurora y metodos de uso. | |
| EA200501667A1 (ru) | Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение | |
| MX2010010151A (es) | Moduladores de cinasa aurora y metodo de uso. | |
| ATE478861T1 (de) | Multizyklische verbindung und verwendungsverfahren | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| DK1567488T3 (da) | Hydroxyethylaminderivater til behandling af Alzheimers sygdom | |
| EA200700352A1 (ru) | Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| UA97816C2 (en) | Compounds modulating c-kit and/or c-fms activity and use thereof | |
| MY147410A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EA200602100A1 (ru) | Соединения и способы для ингибирования митотической прогрессии | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| UA104849C2 (uk) | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus | |
| BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
| MXPA06012796A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| WO2005076979A3 (fr) | Diagnostics et therapeutiques du cancer | |
| MA30720B1 (fr) | Analogues de 2-phenoxypyrimidinone | |
| GB0328900D0 (en) | Novel compounds | |
| EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
| WO2006078576A3 (fr) | Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer | |
| SG162753A1 (en) | Methods of treating cancer and other conditions or disease states using lfmau and ldt | |
| WO2010017240A3 (fr) | Modulateurs de kinase aurora et procédés d’utilisation | |
| EA200300442A1 (ru) | Способы и композиции для лечения воспалительных заболеваний |